21 – 30 of 61
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population : A nationwide Swedish cohort study
(
- Contribution to journal › Article
-
Mark
Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden : From infection severity to impact on care provision
(
- Contribution to journal › Article
-
Mark
Adaptation of the charlson comorbidity index for register-based research in sweden
(
- Contribution to journal › Article
-
Mark
Comparison of treatment retention and response to secukinumab versus tumour necrosis factor inhibitors in psoriatic arthritis
(
- Contribution to journal › Article
-
Mark
Inflammatory hallmarks of lesser prominence in psoriatic arthritis patients starting biologics : A Nordic population-based cohort study
(
- Contribution to journal › Article
- 2020
-
Mark
Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients
(
- Contribution to journal › Article
-
Mark
Healthcare use, work loss and total costs in incident and prevalent Crohn's disease and ulcerative colitis : results from a nationwide study in Sweden
(
- Contribution to journal › Article
- 2019
-
Mark
Biological treatment of ankylosing spondylitis : A nationwide study of treatment trajectories on a patient level in clinical practice
(
- Contribution to journal › Article
-
Mark
Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA : Results from the nationwide Swedish register
(
- Contribution to journal › Article
- 2018
-
Mark
Tumor necrosis factor inhibitors and cancer recurrence in Swedish patients with rheumatoid arthritis A nationwide population-based cohort study
(
- Contribution to journal › Article